Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K, Marcus R, de Vos J, Young AM, Tenant-Flowers M, Orkin C, Johnson M, Chilton D, Gribben JG, Bower M. Montoto S, et al. Among authors: orkin c. J Clin Oncol. 2012 Nov 20;30(33):4111-6. doi: 10.1200/JCO.2011.41.4193. Epub 2012 Oct 8. J Clin Oncol. 2012. PMID: 23045581 Free PMC article.
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures.
Benzie AA, Bansi LK, Sabin CA, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P, Gazzard B, Fisher M, Orkin C, Dunn D, Delpech V, Taylor GP, Walsh JC, Phillips AN; United Kingdom Collaborative HIV Cohort (CHIC) Study Group. Benzie AA, et al. Among authors: orkin c. AIDS. 2007 Jul 11;21(11):1423-30. doi: 10.1097/QAD.0b013e3281532ca7. AIDS. 2007. PMID: 17589188
Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 Cells/mm3.
Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard B, Walsh J, Fisher M, Orkin C, Schwenk A, Gilson R, Easterbrook P, Delpech V, Sabin CA; UK CHIC Study Group. Porter K, et al. Among authors: orkin c. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):202-5. doi: 10.1097/QAI.0b013e31815b1291. J Acquir Immune Defic Syndr. 2008. PMID: 17971709
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study.
Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T, Fisher M, Walsh J, Pillay D, Bansi L, Gazzard B, Easterbrook P, Gilson R, Johnson M, Sabin CA; UK Collaborative HIV Cohort (CHIC) Study. Phillips AN, et al. Among authors: orkin c. Lancet. 2007 Dec 8;370(9603):1923-8. doi: 10.1016/S0140-6736(07)61815-7. Lancet. 2007. PMID: 18068516
Brief communication: rituximab in HIV-associated multicentric Castleman disease.
Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, Orkin C, Webb A, Fisher M, Nelson M, Gazzard B, Stebbing J, Kelleher P. Bower M, et al. Among authors: orkin c. Ann Intern Med. 2007 Dec 18;147(12):836-9. doi: 10.7326/0003-4819-147-12-200712180-00003. Ann Intern Med. 2007. PMID: 18087054 Clinical Trial.
The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.
Sabin CA, Smith CJ, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C, Gazzard B, Porter K, Mackie N, Fisher M, Orkin C, Johnson M, Easterbrook P, Hill T, Phillips AN; UK Collaborative HIV Cohort (CHIC) Study. Sabin CA, et al. Among authors: orkin c. HIV Med. 2009 Jan;10(1):35-43. doi: 10.1111/j.1468-1293.2008.00654.x. Epub 2008 Nov 10. HIV Med. 2009. PMID: 19018876 Free article.
346 results